The European Association of Urology (EAU) guidelines on prostate cancer (PCa) recommend an individualized risk-adapted strategy for early detection of PCa, offering a prostate-specific antigen (PSA) test and digital rectal examination (DRE) to a well-informed man, aware of the related potential risks and benefits with at least ten to fifteen years of life expectancy [1]. This evidence concerns the gene KLK3 and prostate cancer.